Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. METHODS: In 1999, we started an observational study of 1000 APS pat...

ver descrição completa

Detalhes bibliográficos
Autores: Cervera i Segura, Ricard, 1960-, Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Yehuda, de Ramón, Enrique, Buonaiuto, V., Jacobsen, Søren, Zeher, M. M., Tarr, T., Tincani, Angela, Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Meroni, Pierluigi, Derksen, R. H. W. M., de Groot, P. G. D., Baleva, M., Mosca, Marta, Bombardieri, S., Houssiau, Frédéric A., Gris, J-C., Quéré, I., Hachulla, Eric, Vasconcelos, Carlos, Fernández-Nebro, Antonio, Haro, M., Amoura, Zahir, Miyara, M., Tektonidou, Maria, Espinosa Garriga, Gerard, Bertolaccini, M. L., Khamashta, Munther A., Bellisai, F.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2014
País:España
Recursos:Universidad de Barcelona
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/119677
Acesso em linha:https://hdl.handle.net/2445/119677
Access Level:Acceso aberto
Palavra-chave:Síndrome antifosfolipídica
Lupus eritematós
Malalties autoimmunitàries
Morbiditat
Estudi de casos
Antiphospholipid syndrome
Lupus erythematosus
Autoimmune diseases
Morbidity
Case studies
id ES_96dca54221ef3dea29ca08b09b041545
oai_identifier_str oai:diposit.ub.edu:2445/119677
network_acronym_str ES
network_name_str España
repository_id_str
spelling Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsCervera i Segura, Ricard, 1960-Serrano, R.Pons-Estel, G. J.Ceberio-Hualde, L.Shoenfeld, Yehudade Ramón, EnriqueBuonaiuto, V.Jacobsen, SørenZeher, M. M.Tarr, T.Tincani, AngelaTaglietti, M.Theodossiades, G.Nomikou, E.Galeazzi, M.Meroni, PierluigiDerksen, R. H. W. M.de Groot, P. G. D.Baleva, M.Mosca, MartaBombardieri, S.Houssiau, Frédéric A.Gris, J-C.Quéré, I.Hachulla, EricVasconcelos, CarlosFernández-Nebro, AntonioHaro, M.Amoura, ZahirMiyara, M.Tektonidou, MariaEspinosa Garriga, GerardBertolaccini, M. L.Khamashta, Munther A.Bellisai, F.Síndrome antifosfolipídicaLupus eritematósMalalties autoimmunitàriesMorbiditatEstudi de casosAntiphospholipid syndromeLupus erythematosusAutoimmune diseasesMorbidityCase studiesOBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years. RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%. CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.BMJ Publishing Group2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/119677Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2013-204838Annals of the Rheumatic Diseases, 2014, vol. 74, num. 6, p. 1011-1018https://doi.org/10.1136/annrheumdis-2013-204838(c) BMJ Publishing Group, 2014info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1196772026-05-27T06:46:51Z
dc.title.none.fl_str_mv Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
title Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
spellingShingle Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Cervera i Segura, Ricard, 1960-
Síndrome antifosfolipídica
Lupus eritematós
Malalties autoimmunitàries
Morbiditat
Estudi de casos
Antiphospholipid syndrome
Lupus erythematosus
Autoimmune diseases
Morbidity
Case studies
title_short Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
title_full Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
title_fullStr Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
title_full_unstemmed Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
title_sort Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
dc.creator.none.fl_str_mv Cervera i Segura, Ricard, 1960-
Serrano, R.
Pons-Estel, G. J.
Ceberio-Hualde, L.
Shoenfeld, Yehuda
de Ramón, Enrique
Buonaiuto, V.
Jacobsen, Søren
Zeher, M. M.
Tarr, T.
Tincani, Angela
Taglietti, M.
Theodossiades, G.
Nomikou, E.
Galeazzi, M.
Meroni, Pierluigi
Derksen, R. H. W. M.
de Groot, P. G. D.
Baleva, M.
Mosca, Marta
Bombardieri, S.
Houssiau, Frédéric A.
Gris, J-C.
Quéré, I.
Hachulla, Eric
Vasconcelos, Carlos
Fernández-Nebro, Antonio
Haro, M.
Amoura, Zahir
Miyara, M.
Tektonidou, Maria
Espinosa Garriga, Gerard
Bertolaccini, M. L.
Khamashta, Munther A.
Bellisai, F.
author Cervera i Segura, Ricard, 1960-
author_facet Cervera i Segura, Ricard, 1960-
Serrano, R.
Pons-Estel, G. J.
Ceberio-Hualde, L.
Shoenfeld, Yehuda
de Ramón, Enrique
Buonaiuto, V.
Jacobsen, Søren
Zeher, M. M.
Tarr, T.
Tincani, Angela
Taglietti, M.
Theodossiades, G.
Nomikou, E.
Galeazzi, M.
Meroni, Pierluigi
Derksen, R. H. W. M.
de Groot, P. G. D.
Baleva, M.
Mosca, Marta
Bombardieri, S.
Houssiau, Frédéric A.
Gris, J-C.
Quéré, I.
Hachulla, Eric
Vasconcelos, Carlos
Fernández-Nebro, Antonio
Haro, M.
Amoura, Zahir
Miyara, M.
Tektonidou, Maria
Espinosa Garriga, Gerard
Bertolaccini, M. L.
Khamashta, Munther A.
Bellisai, F.
author_role author
author2 Serrano, R.
Pons-Estel, G. J.
Ceberio-Hualde, L.
Shoenfeld, Yehuda
de Ramón, Enrique
Buonaiuto, V.
Jacobsen, Søren
Zeher, M. M.
Tarr, T.
Tincani, Angela
Taglietti, M.
Theodossiades, G.
Nomikou, E.
Galeazzi, M.
Meroni, Pierluigi
Derksen, R. H. W. M.
de Groot, P. G. D.
Baleva, M.
Mosca, Marta
Bombardieri, S.
Houssiau, Frédéric A.
Gris, J-C.
Quéré, I.
Hachulla, Eric
Vasconcelos, Carlos
Fernández-Nebro, Antonio
Haro, M.
Amoura, Zahir
Miyara, M.
Tektonidou, Maria
Espinosa Garriga, Gerard
Bertolaccini, M. L.
Khamashta, Munther A.
Bellisai, F.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Síndrome antifosfolipídica
Lupus eritematós
Malalties autoimmunitàries
Morbiditat
Estudi de casos
Antiphospholipid syndrome
Lupus erythematosus
Autoimmune diseases
Morbidity
Case studies
topic Síndrome antifosfolipídica
Lupus eritematós
Malalties autoimmunitàries
Morbiditat
Estudi de casos
Antiphospholipid syndrome
Lupus erythematosus
Autoimmune diseases
Morbidity
Case studies
description OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years. RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%. CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/119677
url https://hdl.handle.net/2445/119677
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2013-204838
Annals of the Rheumatic Diseases, 2014, vol. 74, num. 6, p. 1011-1018
https://doi.org/10.1136/annrheumdis-2013-204838
dc.rights.none.fl_str_mv (c) BMJ Publishing Group, 2014
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) BMJ Publishing Group, 2014
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414000753639424
score 15,301603